%0 Journal Article %A Qadir, Muhammad Imran %A Zafar, Maria %D 2017 %I Begell House %K tumor susceptibility gene 101 (tsg101), HIV, monoclonal antibody, CB8-2, HIV/AIDS therapy, UEV, TSG101 %N 3 %P 237-246 %R 10.1615/CritRevEukaryotGeneExpr.2017019418 %T TSG101: Tumor Susceptibility Gene 101 (tsg101) Product−Role in Therapy Against HIV/AIDS %U https://www.dl.begellhouse.com/journals/6dbf508d3b17c437,3e1db9ff199ae23c,171ce94b0b6a30d5.html %V 27 %X HIV infection presents a major community health hazard, partially because the HIV virus is capable of evading antiretroviral therapies. Most anti-HIV drugs were intended to target virus-encoded mechanisms; however, some host-encoded molecules comparatively execute a vital role in the life cycle of virus. Thus, these might be considered as target sites for antiviral agents. TSG101 is important among these antiviral therapies because, as a cytoplasmic molecule, it facilitates viral budding and release. In this review, HIV-infected cells have TSG101 on their surface and thus can be used in antibody-based therapies. The development of a monoclonal antibody CB8-2 lessens the assembly of viruses from infected cells. This mechanism represents the potential use of TSG101-directed antibodies to fight against AIDS. %8 2017-09-29